**Sarepta Therapeutics Cuts Workforce Amid Gene Therapy Concerns**
Sarepta Therapeutics Inc., a biotech firm based in Cambridge, Massachusetts, is undergoing significant restructuring, which includes reducing its workforce by over one-third. This decision comes in the wake of two patient deaths linked to its gene therapy for Duchenne muscular dystrophy, raising serious concerns about the company’s future. The company announced on Wednesday that it would lay off approximately 500 employees and pause several drugs in its development pipeline, aiming for an estimated $400 million in annual cost savings.
In response to the U.S. Food and Drug Administration’s (FDA) request, Sarepta will also add a black box warning label to its gene therapy, Elevidys, which is designed to treat a severe muscle disorder. Black box warnings are the most serious safety alerts a drug can carry, indicating potential life-threatening complications, such as liver failure, which has been observed in patients treated with Elevidys.
The layoffs are intended to help Sarepta maintain access to a $600 million revolving credit line and generate cash flow to manage a convertible note due in 2027. Preliminary results for the second quarter revealed total net product revenue of $513 million, with more than half attributed to Elevidys. However, the company faced a setback last month when a second teenage patient died from acute liver failure during treatment with the $3.2 million therapy. Both fatalities involved patients who were non-ambulatory due to the disease.
Following these incidents, Sarepta suspended its revenue guidance for 2025 and committed to a thorough review of its expenses. The company has also paused a clinical trial and halted shipments of Elevidys for non-ambulatory patients. To address safety concerns, Sarepta plans to submit a proposal to the FDA that includes immunosuppressive treatment prior to administering Elevidys, which may help mitigate the risk of complications. Discussions are also underway regarding the resumption of therapy shipments for older boys and young men affected by Duchenne muscular dystrophy.
The FDA is currently investigating the deaths associated with Elevidys, marking a significant challenge for Vinay Prasad, the new head of the agency’s gene therapy division. Prasad, previously an academic at the University of California San Francisco, has been vocal about his criticisms of the FDA’s expedited approval processes, particularly concerning Sarepta’s gene therapies. In March, he expressed concerns on social media, stating that the treatment “seems to be killing kids” and “destroying their livers.”
As Sarepta navigates these challenges, the future of its gene therapy and overall business strategy remains uncertain.
**FAQ**
**What is the significance of the black box warning for Elevidys?**
The black box warning indicates serious safety risks associated with Elevidys, including potential liver failure, which is crucial information for doctors and patients considering this treatment.
